JNJ-73763989

Phase 2Small molecule

Johnson & Johnson

JNJ-73763989 is one of 93 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Hepatitis BActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Hepatitis BPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

JNJ-73763989

Johnson & Johnson

Phase 2

2 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis B Virus Infection6 trials

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04667104·48 enrolled

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03982186·471 enrolled

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04129554·130 enrolled

Show 3 more trials

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05005507·1 enrolled

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05123599·24 enrolled

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04585789·24 enrolled

Adult2 trials

A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04586439·18 enrolled

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04002752·25 enrolled

Chronic Hepatitis2 trials

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05275023·37 enrolled

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04439539·54 enrolled

Hepatic Impairment1 trial

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04208386·16 enrolled

Renal Impairment1 trial

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04963738·29 enrolled

1 more indication

Hepatitis B1 trial

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04535544·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for JNJ-73763989. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-73763989 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-73763989. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

JNJ-73763989

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis B Virus Infection6 trials

Adult2 trials

Chronic Hepatitis2 trials

Hepatic Impairment1 trial

Renal Impairment1 trial

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News